Can a 180 mg controlled‑release diltiazem capsule be administered through a feeding tube?

Diltiazem CD 180 mg Capsules Should NOT Be Administered Through a Feeding Tube

Do not open, crush, or manipulate diltiazem CD (controlled-delivery) capsules for tube administration. The FDA labeling explicitly states that "patients should be cautioned that the diltiazem hydrochloride extended-release capsules should not be opened, chewed or crushed, and should be swallowed whole" 1. This is a critical safety directive that applies regardless of administration route.

Why This Matters for Patient Safety

Controlled-Release Formulation Integrity

Diltiazem CD capsules contain a degradable controlled-release tablet formulation specifically engineered to release diltiazem over 24 hours 1. Opening the capsule destroys this controlled-release mechanism, which would result in:

• Immediate drug dumping rather than sustained release over 24 hours
• Unpredictable plasma concentrations with potential toxicity
• Loss of once-daily dosing efficacy
• Increased risk of hypotension and bradycardia from rapid absorption

Guideline Perspective on Modified Formulations

The 2022 ESPEN guidelines on enteral nutrition emphasize that "crushing medicines should be avoided whenever possible because of the potential risks of exposure to the drug and inaccuracies of drug dosing" 2. Extended-release formulations are specifically problematic because manipulating them converts a controlled-release product into an immediate-release product with completely different pharmacokinetics.

What You Should Do Instead

Consult a Pharmacist Immediately

Involve a pharmacist to identify appropriate alternatives 2. The ESPEN guidelines strongly recommend pharmacist consultation when considering any medication administration through feeding tubes, as they can suggest:

• Immediate-release diltiazem formulations that may be more suitable for tube administration (though still requiring pharmacist guidance)
• Alternative calcium channel blockers available in liquid formulations
• Different rate-control agents appropriate for the patient's specific condition
• IV diltiazem if short-term parenteral therapy is feasible

Key Considerations for Any Alternative

If an alternative must be administered via tube, ensure:

1. Consult the Summary of Product Characteristics for the specific formulation being considered 2
2. Verify tube placement and size - drug delivery site affects bioavailability 2
3. Flush the tube properly before and after administration to prevent occlusion 2
4. Use appropriate ENFit syringes to avoid dosing errors and misconnections 2
5. Monitor for altered drug efficacy since tube administration may affect absorption 2

Critical Pitfalls to Avoid

• Never assume generic equivalence for tube administration - different formulations may behave differently when manipulated
• Do not mix medications together in the tube unless compatibility is confirmed
• Avoid acidic environments for acid-labile drugs, which can cause degradation 3
• Remember that using products outside their labeled indications carries additional prescriber responsibility for adverse events 2

The Bottom Line

This is an off-label use that violates the FDA-approved product labeling and could result in serious patient harm from uncontrolled drug release. The appropriate action is to work with a pharmacist to identify a suitable alternative formulation or medication that is compatible with feeding tube administration while maintaining therapeutic efficacy and patient safety.